Bellicum Pharmaceuticals (BLCM)
NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Price & Analysis

687 Followers

BLCM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.60 - $2.20
Previous Close$1.27
Volume21.95K
Average Volume (3M)38.33K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$28.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-2.6
Beta0.41
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.49
Shares Outstanding8,613,527
R-Squared0.13
Standard Deviation0.19
10 Day Avg. Volume82,683
30 Day Avg. Volume38,331
Price to Book (P/B)1.38
Price to Sales (P/S)11.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha-0.07
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BLCM FAQ

What was Bellicum Pharmaceuticals’s price range in the past 12 months?
Bellicum Pharmaceuticals lowest stock price was $0.60 and its highest was $2.20 in the past 12 months.
    What is Bellicum Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Bellicum Pharmaceuticals’s upcoming earnings report date?
    Bellicum Pharmaceuticals’s upcoming earnings report date is Mar 14, 2023 which is in 42 days.
      How were Bellicum Pharmaceuticals’s earnings last quarter?
      Bellicum Pharmaceuticals released its earnings results on Nov 10, 2022. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.41.
        Is Bellicum Pharmaceuticals overvalued?
        According to Wall Street analysts Bellicum Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Bellicum Pharmaceuticals pay dividends?
          Bellicum Pharmaceuticals does not currently pay dividends.
          What is Bellicum Pharmaceuticals’s EPS estimate?
          Bellicum Pharmaceuticals’s EPS estimate is -$0.93.
            How many shares outstanding does Bellicum Pharmaceuticals have?
            Bellicum Pharmaceuticals has 8,613,527 shares outstanding.
              What happened to Bellicum Pharmaceuticals’s price movement after its last earnings report?
              Bellicum Pharmaceuticals reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went up 0.885%.
                Which hedge fund is a major shareholder of Bellicum Pharmaceuticals?
                Currently, no hedge funds are holding shares in BLCM

                ---

                Bellicum Pharmaceuticals Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -16.44%
                12-Months-Change

                Fundamentals

                Return on Equity
                -108.01%
                Trailing 12-Months
                Asset Growth
                39.82%
                Trailing 12-Months
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Bellicum Pharmaceuticals

                Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Kintara Therapeutics
                QSAM Biosciences
                ProtoKinetix
                Ridgefield Acquisition
                Calithera Bio

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis